奥沙利铂在结肠癌辅助治疗中的应用 - Suppr

Suppr

超能文献

Oxaliplatin in the adjuvant treatment of colon cancer.

作者信息

Barton Mary Kay

出版信息

CA Cancer J Clin. 2012 Jan-Feb;62(1):3-4. doi: 10.3322/caac.21131. Epub 2011 Nov 16.

DOI:10.3322/caac.21131

PMID:22095255

Abstract

摘要

相似文献

Oxaliplatin in the adjuvant treatment of colon cancer.奥沙利铂在结肠癌辅助治疗中的应用

CA Cancer J Clin. 2012 Jan-Feb;62(1):3-4. doi: 10.3322/caac.21131. Epub 2011 Nov 16.

Oxaliplatin shows significant benefit over standard therapy in early-stage colon cancer.在早期结肠癌中，奥沙利铂相较于标准疗法显示出显著的疗效。

Oncology (Williston Park). 2004 Sep;18(10):1313.

FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer.FOLFOX方案用于II期结肠癌？对美国食品药品监督管理局（FDA）近期批准奥沙利铂用于III期结肠癌辅助治疗的评论。

J Clin Oncol. 2005 May 20;23(15):3311-3. doi: 10.1200/JCO.2005.11.691.

[II. Postoperative adjuvant chemotherapy for colon cancer. 1. Is oxaliplatin combination the most effective chemotherapy for colon cancer?].[二、结肠癌术后辅助化疗。1. 奥沙利铂联合化疗是结肠癌最有效的化疗方案吗？]

Gan To Kagaku Ryoho. 2012 Nov;39(11):1642-.

Oxaliplatin (Eloxatin) for advanced colon cancer.奥沙利铂（乐沙定）用于晚期结肠癌。

Med Lett Drugs Ther. 2003 Jan 20;45(1148):7-8.

Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: the results are in.奥沙利铂或伊立替康作为结肠癌辅助治疗的结果已见分晓。

J Clin Oncol. 2009 Jul 1;27(19):3082-4. doi: 10.1200/JCO.2009.22.2919. Epub 2009 May 18.

Adjuvant therapy of colon cancer: current status and future directions.结肠癌的辅助治疗：现状与未来方向

Cancer J. 2007 May-Jun;13(3):192-7. doi: 10.1097/PPO.0b013e318074d26e.

[II. Postoperative adjuvant chemotherapy for colon cancer. 2. Oxaliplatin combination does not help better treatment outcome].[二、结肠癌的术后辅助化疗。2. 奥沙利铂联合方案无助于改善治疗效果]

Gan To Kagaku Ryoho. 2012 Nov;39(11):1646-9.

New therapeutic options in colon cancer: focus on oxaliplatin.结肠癌的新治疗选择：聚焦奥沙利铂

Clin J Oncol Nurs. 2002 May-Jun;6(3):131-7. doi: 10.1188/02.CJON.131-137.

Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: a case report.奥沙利铂在一名结肠癌患者辅助治疗期间引起溶血性贫血：一例病例报告

Anticancer Drugs. 2007 Mar;18(3):297-300. doi: 10.1097/CAD.0b013e3280102f4b.

引用本文的文献

Transcriptomic Analysis Identifies Complement Component 3 as a Potential Predictive Biomarker for Chemotherapy Resistance in Colorectal Cancer.转录组分析确定补体成分3作为结直肠癌化疗耐药的潜在预测生物标志物。

Front Mol Biosci. 2021 Oct 15;8:763652. doi: 10.3389/fmolb.2021.763652. eCollection 2021.

A New Oxaliplatin Resistance-Related Gene Signature With Strong Predicting Ability in Colon Cancer Identified by Comprehensive Profiling.通过综合分析鉴定出一种在结肠癌中具有强大预测能力的新的奥沙利铂耐药相关基因特征。

Front Oncol. 2021 May 7;11:644956. doi: 10.3389/fonc.2021.644956. eCollection 2021.

Pharmaceutical immunoglobulin G impairs anti-carcinoma activity of oxaliplatin in colon cancer cells.药物免疫球蛋白 G 削弱奥沙利铂对结肠癌细胞的抗癌活性。

Br J Cancer. 2021 Apr;124(8):1411-1420. doi: 10.1038/s41416-021-01272-6. Epub 2021 Feb 9.

Association between glioblastoma cell-derived vessels and poor prognosis of the patients.胶质母细胞瘤细胞来源的血管与患者预后不良之间的关系。

Cancer Commun (Lond). 2020 May;40(5):211-221. doi: 10.1002/cac2.12026. Epub 2020 May 2.

Overexpression of long non-coding RNA colon cancer-associated transcript 2 is associated with advanced tumor progression and poor prognosis in patients with colorectal cancer.长链非编码RNA结肠癌相关转录本2的过表达与结肠癌患者的肿瘤进展及预后不良相关。

Oncol Lett. 2017 Dec;14(6):6907-6914. doi: 10.3892/ol.2017.7049. Epub 2017 Sep 25.

Overexpression of Rab1B and MMP9 predicts poor survival and good response to chemotherapy in patients with colorectal cancer.Rab1B和基质金属蛋白酶9（MMP9）的过表达预示着结直肠癌患者生存率低且对化疗反应良好。

Aging (Albany NY). 2017 Mar 18;9(3):914-931. doi: 10.18632/aging.101200.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验